Rena Therapeutics
Tokyo
About Rena Therapeutics
In the pharmaceutical market, attention has been focused on nucleic acid drugs to meet unmet medical needs such as cancer and intractable diseases.This is because nucleic acid drugs have the following advantages.It is possible to target intracellular drug molecules that could not be targeted by conventional drugsDrug discovery research is possible for any gene as long as there is technology to deliver nucleic acids to the expression siteMore specific than low molecular weight compounds and less susceptible to side effects Unlike antibody drugs, nucleic acid drugs can be manufactured by chemical synthesis at a relatively low cost.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.2M
- Funding stage: M&A
- Last round: Series Unknown (Jun 2017)
- Website: renatherapeutics.com
- Phone: +81 03-4243-6081
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Health Diagnostics, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/rena-therapeutics-185909 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.